By Steven Scheer JERUSALEM, Jan 28 (Reuters) - Teva Pharmaceutical Industries reported strong quarterly results on Wednesday ...

Teva Pharmaceutical Industries (TEVA) shares snapped six straight sessions of gains, as the stock closed 0.4% lower at $33.07 on Thursday. The generic drugmaker gained about 6% in the preceding ...

Teva beat fourth-quarter estimates as drug sales surged, led by Austedo and Ajovy, while the company forecast steady earnings ...

Teva Pharmaceutical Industries (NYSE:TEVA) used its fourth-quarter 2025 earnings call to emphasize progress under its “Pivot to Growth” strategy, pointing to continued momentum in its innovative ...

Teva President and CEO Richard Francis joins 'Mad Money' host Jim Cramer to talk quarterly results, its growth strategy, ...

Teva (TEVA) stock dips as the company, with its Q4 2025 results, projects a revenue drop for this year. Read more here.

Greenlight Capital, an investment management company, released its fourth-quarter 2025 investor letter. A copy of the letter ...

Under CEO Richard Francis’ “Pivot to Growth” strategy, Teva Pharmaceutical Industries has undergone a significant ...

A federal judge denied Teva's bid to delay the first Paragard bellwether trial, keeping a January start date for claims tied to IUD breakage injuries.

Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in ...

The drugmaker has recruited Will Forte, who appeared on “SNL” for nearly a decade in the aughts, perhaps most memorably as ...

The announcement follows a previous recall of 800-gram packages of Nutrilon Phase 1 due to concerns about the presence of the ...